Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.4M
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+24.4M
-
Total reported value, excl. options
-
$601M
-
Value change
-
+$524M
-
Put/Call ratio
-
0.07
-
Number of buys
-
42
-
Number of sells
-
-7
-
Price
-
$21.52
Significant Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q4 2023
59 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock as of Q4 2023.
Spyre Therapeutics, Inc. - Common Stock (SYRE) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 60.4M outstanding shares and own 46.4% of the company stock.
Largest 10 shareholders include FMR LLC (3.79M shares), PERCEPTIVE ADVISORS LLC (2.61M shares), VR Adviser, LLC (2.37M shares), RTW INVESTMENTS, LP (2.23M shares), Deep Track Capital, LP (1.95M shares), COMMODORE CAPITAL LP (1.88M shares), Avoro Capital Advisors LLC (1.84M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1M shares), Cormorant Asset Management, LP (937K shares), and EcoR1 Capital, LLC (887K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.